MIRA
INFORM REPORT
|
Report Date : |
18.08.2008 |
IDENTIFICATION
DETAILS
|
Name : |
OMNIACTIVE HEALTH TECHNOLOGIES, INC. |
|
|
|
|
Registered Office : |
51 JFK Parkway, 1Fl W, Short
Hills, NJ 07078 |
|
|
|
|
Country : |
United States |
|
|
|
|
Date of Incorporation : |
19.10. 2004 |
|
|
|
|
Legal Form : |
Corporation for Profit |
|
|
|
|
Line of Business : |
Manufactures
Pharmaceutical Preparations. |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 200,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
REQUIRED CREDIT |
ADVISED CREDIT |
|
MAXIMUM |
200,000 USD |
GEOPOLITICS
|
POLITICAL DATA |
ECONOMIC DATA |
||
|
FORM OF GOVERNMENT ECONOMIC RISK |
Federal
|
CURRENCY BRANCH SITUATION |
USD Satisfying |
IDENTIFICATION
|
Company Name: |
OMNIACTIVE HEALTH TECHNOLOGIES, INC. |
||
|
Address: |
51 JFK
Parkway, 1Fl W, Short Hills,
NJ 07078 USA |
||
|
Phone: Facsimile: ID: State: Managers: |
+ 1 (908) 770-6828 + 1 (877) 588-3629 0100935387 New Jersey Hiren Doshi, President |
Date founded: |
Oct 19, 2004
Corporation for Profit N.A. N.A. 30 employees |
|
Legal form: |
|||
|
Stock: Value: |
|||
|
Staff: |
|||
|
Business: |
Manufactures pharmaceutical preparations. |
||
BANKS
Bank of America
BUSINESS
Business & Operations:
Omniactive Health
Technologies, Inc. is a private company located in Short Hills, New Jersey. The
company’s line of business is manufacturer of pharmaceutical preparations.
Industry Overview:
About 1,500 companies in the US manufacture and market medicinal drugs,
with combined annual US revenue over $200 billion. Large US manufacturers include
Merck, Pfizer, Bristol-Myers Squibb, Abbott, and Eli Lilly. The industry is
highly concentrated: the 50 largest companies control more than 80 percent of
the market.
The traditional drug manufacturing industry increasingly overlaps with
the biotechnology industry, which is a source of many new medical treatments.
To a large extent, traditional drug manufacturers are becoming development and
marketing companies that acquire new drugs from smaller research companies.
The industry is marked by rapid advances in scientific knowledge that
produce ever-more effective medicines. Profitability is determined mainly by
the ability to discover new drugs. The industry is dominated by the large
manufacturers/marketers that manufacture drugs, have large research operations,
and also have large clinical testing, marketing, and distribution capabilities.
Small companies are mainly research operations or manufacturers of
non-prescription products. Because of the high value of the product, average
revenue per employee is a very high $600,000.
SHAREHOLDERS – SUBSIDIARIES
– MANAGERS
The director of the company
is:
Hiren Doshi, President.
The foreign parent company
is Omniactive Health Technologies PVT.
FINANCIALS – COMMERCIAL TRENDS
AND FORECAST
Omniactive Health
Technologies, Inc. does not publish any financial statement.
However
our financial sources could provide us with the following information:
|
Fiscal Year In USD |
12/31/2007 |
|
Turnover |
6,300,000 |
|
Operating Profit |
185,000 |
|
Net Income |
120,000 |
|
Net Worth |
300,000 |
|
Liabilities |
30,000 |
LEGALS
0 Suits
0 Judgments
0 Liens
0 Collection Claims
Reported
0 NSF Cheques Reported
1 UCC Filing in 2007 &
2006 by Amerisource Funding Inc securing Accounts & Proceeds. Amount: NA
All previous UCC Filings
have been cleared
RATING
Local credit bureau gave a good credit rate.
The Company is in “good standing”.
This means that all local and federal taxes were paid on due date.
-
The cash flow is good.
-
Payments are made on a 45 days basis.
Our final opinion:
This is a small company
working in the worldwide.
A credit line may be
considered.
SUMMARY
|
FINANCIAL SUMMARY |
DEBT COLLECTIONS
AND PAYMENTS |
||
|
PROFITABILITY INDEBTNESS CASH |
Low Controlled Good |
PUBLIC PAYMENTS |
See above Regular |
ADVISED
CREDIT
200,000 USD
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.43.28 |
|
UK Pound |
1 |
Rs.80.89 |
|
Euro |
1 |
Rs.63.80 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)